Literature DB >> 7805037

The novel activation of ABL by fusion to an ets-related gene, TEL.

P Papadopoulos1, S A Ridge, C A Boucher, C Stocking, L M Wiedemann.   

Abstract

In human leukemia, activation of the ABL proto-oncogene locus on chromosome 9 most commonly occurs as a result of its fusion to the BCR locus on chromosome 22. The resulting chimeric protein displays an elevated tyrosine kinase activity. We have identified a novel activation of ABL which involves a gene located on chromosome 12, designated TEL. Like BCR, TEL is fused in-frame with ABL and produces a fusion protein with an elevated tyrosine kinase activity when assayed in an immune complex. The amino-terminal sequences of TEL encode a helix-loop-helix motif which may mediate dimerization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7805037

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Tel, a frequent target of leukemic translocations, induces cellular aggregation and influences expression of extracellular matrix components.

Authors:  L Van Rompaey; W Dou; A Buijs; G Grosveld
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression.

Authors:  C A Kim; M L Phillips; W Kim; M Gingery; H H Tran; M A Robinson; S Faham; J U Bowie
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

4.  The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Authors:  A Buijs; L van Rompaey; A C Molijn; J N Davis; A C Vertegaal; M D Potter; C Adams; S van Baal; E C Zwarthoff; M F Roussel; G C Grosveld
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

5.  Regression of a congenital mesoblastic nephroma.

Authors:  Sarah Whittle; Ankush Gosain; Petagay Y Scott Brown; Lairsa Debelenko; Susana Raimondi; Judith A Wilimas; Jesse J Jenkins; Andrew M Davidoff
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

6.  Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL.

Authors:  L C Wang; F Kuo; Y Fujiwara; D G Gilliland; T R Golub; S H Orkin
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

7.  A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.

Authors:  K Okuda; A D'Andrea; R A Etten; J D Griffin
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

8.  An efficient rapid system for profiling the cellular activities of molecular libraries.

Authors:  Jonathan S Melnick; Jeff Janes; Sungjoon Kim; Jim Y Chang; Daniel G Sipes; Drew Gunderson; Laura Jarnes; Jason T Matzen; Michael E Garcia; Tami L Hood; Ronak Beigi; Gang Xia; Richard A Harig; Hayk Asatryan; S Frank Yan; Yingyao Zhou; Xiang-Ju Gu; Alham Saadat; Vicki Zhou; Frederick J King; Christopher M Shaw; Andrew I Su; Robert Downs; Nathanael S Gray; Peter G Schultz; Markus Warmuth; Jeremy S Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

9.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

Review 10.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.